Randomised double-blind, placebo-controlled trial of selenium supplementation in adult asthma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN31432640

Enrollment

200

Registered

2006-05-15

Start date

2002-05-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult asthma Respiratory Asthma

Interventions

Selenium supplement 100 microgram (one tablet per day) versus placebo supplied by Pharma Nord, Denmark. The product (SelenoPrecise ™) is a yeast preparation grown in a selenium-rich medium. Placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Asthma symptoms in last month 2. Prescribed inhaled steroids in last six months 3. Not taking selenium supplements

Exclusion criteria

Exclusion criteria: 1. Inability to give informed consent 2. Inability to swallow tablets 3. Pregnancy or lactation or intention to become pregnant during the trial period 3. Renal or liver disease 4. Known yeast intolerance

Design outcomes

Primary

Measure	Time frame
Asthma-related quality of life	—

Secondary

Measure	Time frame
1. Lung function 2. Asthma symptom scores 3. Peak flow 4. Bronchodilator usage	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026